Knight Therapeutics Expands MINJUVI® (tafasitamab) Indications
Knight Therapeutics Inc., a prominent specialty pharmaceutical firm focused on the pan-American market, has announced a significant move in Brazil. The company's Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the national health regulatory agency. This application seeks approval for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for treating adult patients who have previously undergone treatment for follicular lymphoma (FL).
The Journey of MINJUVI in Brazil
This regulatory submission is part of Knight's broader strategy to expand access to innovative cancer treatments in Latin America. The company previously launched MINJUVI in Brazil in early 2024, targeting adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which comprises a significant portion of hematological malignancies. The recent application for a new indication illustrates Knight's dedication to enhancing therapeutic options for patients.
Innovative Treatment Options
Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics, commented on this advancement, stating, “This regulatory submission for a new indication for tafasitamab in relapsed or refractory FL underscores our commitment to innovation in cancer care.” She emphasized that if approved, this combination therapy would offer a vital new treatment path for eligible adult patients in Brazil.
Understanding Follicular Lymphoma
Follicular Lymphoma is recognized as the most common type of indolent, or slow-growing, non-Hodgkin lymphoma. Recent data from the National Cancer Institute in Brazil has revealed that the expected incidence of non-Hodgkin lymphoma in the general population is approximately 5.57 per 100,000 individuals. Notably, follicular lymphoma is expected to account for around 20% to 25% of adult non-Hodgkin lymphoma cases, highlighting the need for effective treatment options for this patient population.
InMIND Trial Insights
The foundation of the supplemental application is rooted in the results of the pivotal Phase 3 inMIND trial, which randomly assigned 548 participants with relapsed or refractory FL to receive tafasitamab in conjunction with lenalidomide and rituximab. Key findings revealed that patients receiving this combination experienced significantly improved progression-free survival (PFS) compared to those given a placebo. The treatment group showcased a median PFS of 22.4 months versus 13.9 months in the placebo cohort, translating to a remarkable 57% reduction in the risk of disease progression or relapse.
MINJUVI® (tafasitamab) Overview
MINJUVI® is a humanized Fc-modified cytolytic monoclonal antibody targeting CD19. Its unique formulation fosters B-cell lysis through mechanisms such as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). In the United States, the drug is marketed under the name MONJUVI® and has received FDA approval for the treatment of adult patients with relapsed or refractory follicular lymphoma, underscoring its growing importance in oncology.
Both MONJUVI and MINJUVI have been integral to Knight Therapeutics' portfolio, proving their significance in treating relapsed or refractory DLBCL. This comprehensive regulatory push marks a pivotal milestone in the journey of tafasitamab as a crucial therapeutic option in Brazil and Latin America.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. is committed to expanding access to essential pharmaceuticals throughout Canada and Latin America. The company operates distinct subsidiaries, including United Medical and Biotoscana Farma, each contributing to advancing healthcare solutions. Shares of Knight Therapeutics Inc. are traded on the TSX under the ticker symbol GUD. For further inquiries or detailed information about Knight's initiatives, you may contact the company directly.
Frequently Asked Questions
What recent regulatory step has Knight Therapeutics taken in Brazil?
Knight Therapeutics has submitted a supplemental application to ANVISA to expand the indication for MINJUVI® for treating previously treated follicular lymphoma.
What is the significance of the inMIND trial findings?
The inMIND trial revealed that the combination of tafasitamab, lenalidomide, and rituximab significantly extends progression-free survival in patients with relapsed or refractory follicular lymphoma.
What does MINJUVI® target?
MINJUVI® targets CD19, leading to the destruction of B-cells through various immune mechanisms.
How does Knight Therapeutics support patients in Latin America?
Knight Therapeutics is focused on acquiring and commercializing innovative treatments to enhance patient care across Latin America, particularly in oncology.
What therapies are being developed by Knight Therapeutics?
In addition to MINJUVI®, Knight Therapeutics works on several innovative therapies aimed at treating various hematological malignancies and other health conditions.
